Literature DB >> 7862854

Aversive properties of the kappa opioid agonist U50,488 in the week-old rat pup.

G A Barr1, S Wang, S Carden.   

Abstract

mu Opioids have been shown to produce analgesia and to be reinforcing during the first week of life in the rat. kappa Opioids also have analgesic actions in both the infant and adult, but can be aversive in the mature animal. We examined the aversive effects of the kappa opioid agonist U50,488 during the first postnatal week in the rat pup in three ways. In the first experiment, U50,488, injected peripherally (1.0-30.0 mg/kg), was paired with an odor and pups were tested 8 h later for positional preference for avoidance of that odor. This task is similar to conditioned preference/aversion tests used with adult animals. Both 3- and 7-day-old pups learned to avoid the odor adulterated side at the two higher doses. When exposed to odors previously associated with U50,488, pups at both ages decreased locomotor activity. In a second experiment, acute treatment with U50,488 increased ultrasonic distress vocalizations (USV) equally at 3 and 7 days of age, increased locomotor activity, and decreased rectal temperature. Neither of the latter two effects was correlated with the increase in USV production. The third experiment showed that conditioned odor cues increased USV 8 h later in 3- and 7-day-old pups at 1.0-10.0 mg/kg without changes in activity or rectal temperature. The results from these studies suggest that U50,488 can produce aversions in the neonatal rat pup as it does in the adult.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7862854     DOI: 10.1007/bf02245218

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Ultrasonic vocalizations by rat pups in the cold: an acoustic by-product of laryngeal braking?

Authors:  M S Blumberg; J R Alberts
Journal:  Behav Neurosci       Date:  1990-10       Impact factor: 1.912

Review 2.  The infant rat separation paradigm: a novel test for novel anxiolytics.

Authors:  J T Winslow; T R Insel
Journal:  Trends Pharmacol Sci       Date:  1991-11       Impact factor: 14.819

3.  Kappa receptors mediate the peripheral aversive effects of opiates.

Authors:  A Bechara; D van der Kooy
Journal:  Pharmacol Biochem Behav       Date:  1987-10       Impact factor: 3.533

4.  Kappa opioid receptor-mediated analgesia in the developing rat.

Authors:  G A Barr; W Paredes; K L Erickson; R S Zukin
Journal:  Brain Res       Date:  1986-10       Impact factor: 3.252

5.  Behavioural effects of selective mu-, kappa-, and delta-opioid agonists in neonatal rats.

Authors:  H C Jackson; I Kitchen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

7.  Ultrasonic vocalization, laryngeal braking, and thermogenesis in rat pups: a reappraisal.

Authors:  M A Hofer; H N Shair
Journal:  Behav Neurosci       Date:  1993-04       Impact factor: 1.912

8.  Odor aversion learning by the rat fetus.

Authors:  W P Smotherman
Journal:  Physiol Behav       Date:  1982-11

9.  Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning.

Authors:  R F Mucha; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  14 in total

1.  Endogenous opioids as substrates for ethanol intake in the neonatal rat: The impact of prenatal ethanol exposure on the opioid family in the early postnatal period.

Authors:  Kelly Bordner; Terrence Deak
Journal:  Physiol Behav       Date:  2015-02-07

2.  Ontogenetic differences in ethanol's motivational properties during infancy.

Authors:  Michael E Nizhnikov; Ricardo Marcos Pautassi; Elena I Varlinskaya; Pouyan Rahmani; Norman E Spear
Journal:  Alcohol       Date:  2012-03-21       Impact factor: 2.405

3.  The Central Reinforcing Properties of Ethanol Are Mediated by Endogenous Opioid Systems: Effects of Mu and Kappa Opioid Antagonists.

Authors:  Michael E Nizhnikov; Elena I Varlinskaya; Norman E Spear
Journal:  Rev Argent Cienc Comport       Date:  2009

Review 4.  Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics.

Authors:  K A Miczek; E M Weerts; J A Vivian; H M Barros
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

Review 5.  A Motivational and Neuropeptidergic Hub: Anatomical and Functional Diversity within the Nucleus Accumbens Shell.

Authors:  Daniel C Castro; Michael R Bruchas
Journal:  Neuron       Date:  2019-05-08       Impact factor: 17.173

6.  Ontogeny of ethanol intake in alcohol preferring (P) and alcohol nonpreferring (NP) rats.

Authors:  Ricardo Marcos Pautassi; Michael E Nizhnikov; Eric Truxell; Elena I Varlinskaya; Norman E Spear
Journal:  Dev Psychobiol       Date:  2010-11-17       Impact factor: 3.038

Review 7.  Changing mechanisms of opiate tolerance and withdrawal during early development: animal models of the human experience.

Authors:  Gordon A Barr; Anika McPhie-Lalmansingh; Jessica Perez; Michelle Riley
Journal:  ILAR J       Date:  2011

8.  Affective cue-induced escalation of alcohol self-administration and increased 22-kHz ultrasonic vocalizations during alcohol withdrawal: role of kappa-opioid receptors.

Authors:  Anthony L Berger; Angela M Williams; Molly M McGinnis; Brendan M Walker
Journal:  Neuropsychopharmacology       Date:  2012-11-06       Impact factor: 7.853

9.  Adolescent experience affects postnatal ultrasonic vocalizations and gene expression in future offspring.

Authors:  Caroline M Bodi; Fair M Vassoler; Elizabeth M Byrnes
Journal:  Dev Psychobiol       Date:  2016-03-21       Impact factor: 3.038

10.  Pharmacological activation of kappa opioid receptors: aversive effects in adolescent and adult male rats.

Authors:  Rachel I Anderson; Melissa Morales; Linda P Spear; Elena I Varlinskaya
Journal:  Psychopharmacology (Berl)       Date:  2013-04-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.